The DNA-testing company is exploring its options, including a business combination and the sale of some or all of its assets.
Holding released a new polygenic risk score report on the genetics of osteoporosis for 23andMe+ Premium members. The report ...
By the 2023 fiscal year, 23andMe had reported a net loss of $312 million and its individual share price has plummeted a ...
23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter ...
At-home DNA testing is no longer in high demand — and critics have raised concerns about unreliable tests and privacy.
Company Notes Continued Concerns Regarding Liquidity and Consideration of Potential Ways to Address Operational and Financial ...
23andMe Holding Co. ( ME, Financials) announced that its board's Special Committee is reviewing strategic alternatives, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback